CYP2C9*62 is assigned uncertain funciton due to inadequate evidence. One in vitro study found the protein expression of CYP2C9*62 was significantly lower than that of the wild-type, and its metabolic activity was also significantly decreased after the addition of three typical CYP2C9 probe drugs (tolbutaminde, losartan, and diclofenac), suggesting that the new mutant can dramatically affect the metabolism of CYP2C9 drugs in vitro (32531309). Consensus was not achieved among experts and therefore uncertain function was assigned.